Eli Lilly and Company $LLY Shares Sold by Longbow Finance SA

Longbow Finance SA trimmed its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 29.7% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 13,316 shares of the company’s stock after selling 5,637 shares during the period. Longbow Finance SA’s holdings in Eli Lilly and Company were worth $10,160,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also made changes to their positions in the company. IMA Advisory Services Inc. increased its stake in Eli Lilly and Company by 51.9% in the third quarter. IMA Advisory Services Inc. now owns 120 shares of the company’s stock valued at $92,000 after purchasing an additional 41 shares during the last quarter. Missouri Trust & Investment Co lifted its position in Eli Lilly and Company by 26.9% in the third quarter. Missouri Trust & Investment Co now owns 1,415 shares of the company’s stock valued at $1,080,000 after acquiring an additional 300 shares during the last quarter. Columbia Bank grew its holdings in shares of Eli Lilly and Company by 5.5% during the third quarter. Columbia Bank now owns 5,213 shares of the company’s stock worth $4,309,000 after purchasing an additional 274 shares during the last quarter. Abich Financial Wealth Management LLC acquired a new stake in shares of Eli Lilly and Company during the third quarter worth about $134,000. Finally, Assetmark Inc. boosted its position in shares of Eli Lilly and Company by 6.0% in the 3rd quarter. Assetmark Inc. now owns 55,360 shares of the company’s stock valued at $42,239,000 after purchasing an additional 3,142 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Robust fundamentals and guidance — Lilly reported a strong Q4 beat and raised FY2026 outlook, underscoring surging GLP‑1/weight‑loss revenue and underpinning investor optimism. How to Play Eli Lilly Stock Following a Robust Q4 Earnings Report
• Positive Sentiment: Pre‑launch inventory build — Lilly filed that it has about $1.5 billion of pre‑launch inventory for its experimental oral weight‑loss pill, signaling management confidence in commercialization and readiness to capture market share if approved. Eli Lilly builds $1.5 billion stockpile of weight-loss pill ahead of FDA decision
• Positive Sentiment: M&A to expand pipeline — Lilly agreed to acquire Orna Therapeutics for up to $2.4B, adding an RNA platform that diversifies growth beyond GLP‑1s and supports longer‑term R&D optionality. Eli Lilly to acquire ‘world’s most innovative biotech startup’ for up to $2.4B
• Positive Sentiment: Analyst upgrades & institutional buying — recent upgrades (Freedom Capital to strong‑buy) and a stake increase by Fisher Asset Management reinforce buy‑side conviction. Zacks / analyst coverage
• Neutral Sentiment: Industry tailwinds from AI and biotech momentum — broader analyst pieces highlight AI drug‑discovery and biotech sector strength that could benefit Lilly longer term, but these are thematic rather than company‑specific catalysts. 2 Biotech Stocks to Buy as AI Drug Discovery Lifts Off
• Neutral Sentiment: Market commentary and price forecasts — multiple outlets publish bullish multi‑year forecasts and “reasons to buy” writeups; useful for sentiment but speculative for near‑term price moves. Stock Price Prediction and Forecast 2026-2030
• Negative Sentiment: Regulatory binary risk — the April FDA decision on the oral weight‑loss pill is binary and could trigger significant volatility; the large pre‑launch build increases both upside on approval and downside on rejection or delays. Eli Lilly builds $1.5 billion stockpile of weight-loss pill ahead of FDA decision
• Negative Sentiment: Competitive dynamics — Novo Nordisk remains a dominant competitor in obesity drugs; market‑share battles, pricing pressure or faster rival launches could blunt Lilly’s growth trajectory. Eli Lilly vs Novo Nordisk in the Weight Loss Drug Market

Eli Lilly and Company Stock Performance

Shares of LLY opened at $1,038.59 on Friday. The stock has a market capitalization of $981.86 billion, a P/E ratio of 45.25, a P/E/G ratio of 1.18 and a beta of 0.39. The company has a debt-to-equity ratio of 1.71, a quick ratio of 1.24 and a current ratio of 1.55. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,133.95. The company’s fifty day moving average is $1,051.78 and its two-hundred day moving average is $904.70.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $7.48 by $0.06. The firm had revenue of $19.29 billion during the quarter, compared to analysts’ expectations of $17.85 billion. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 112.50%. The firm’s revenue for the quarter was up 42.6% on a year-over-year basis. During the same period in the prior year, the company posted $5.32 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, sell-side analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date is Friday, February 13th. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s payout ratio is 26.14%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. Wells Fargo & Company boosted their price objective on Eli Lilly and Company from $1,200.00 to $1,280.00 and gave the company an “overweight” rating in a research note on Thursday, February 5th. Leerink Partners lifted their target price on shares of Eli Lilly and Company from $1,234.00 to $1,296.00 and gave the company an “outperform” rating in a report on Thursday, February 5th. Bank of America reduced their price target on shares of Eli Lilly and Company from $1,286.00 to $1,268.00 and set a “buy” rating for the company in a research report on Monday, December 15th. Guggenheim lowered their price objective on shares of Eli Lilly and Company from $1,163.00 to $1,161.00 and set a “buy” rating on the stock in a research report on Tuesday, January 20th. Finally, HSBC restated a “hold” rating and issued a $1,070.00 price objective on shares of Eli Lilly and Company in a research note on Wednesday, December 10th. Three research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and an average price target of $1,217.71.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.